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BACKGROUND & AIMS  
Donation after circulatory death (DCD) in the UK has tripled in the last decade. 
However, outcomes following DCD liver transplantation are poorer than for brain-
stem death (DBD) liver transplants.  
This study examines whether a recipient to should accept a “poorer quality” DCD 
organ, or wait longer for a “better” DBD organ.  
METHODS 
Survival following deceased donor liver transplantation performed between 2008 and 
2015 was compared by Cox regression modelling to assess the impact on patient 
survival of accepting a DCD liver compared to deferring for a potential DBD 
transplant.  
RESULTS 
953 (23%) of the 3949 liver transplantations performed utilised DCD donors. Five-
year transplant survival was poorer following DCD than DBD transplantation (69·1% 
(DCD) vs 78·3% (DBD); p <0·0001: adjusted hazard ratio [HR] = 1·65, 1·40 – 1·94).  
Of the 5798 patients registered on the transplant list, 1325 (23%) died or were 
removed from the list without receiving a transplant. Patients who received DCD 
livers had a lower risk-adjusted hazard of death than those who remained on the 
waiting list for a potential DBD organ (adjusted HR 0·55, 0·47 – 0·65). The greatest 
survival benefit was in those with the most advanced liver disease (adjusted HR 0·19 
(0·07, 0·50).  
CONCLUSIONS 
Although DCD liver transplantation has poorer transplant outcomes, the individual’s 
survival is enhanced by accepting a DCD offer particularly for patients with more 
severe liver disease. DCD liver transplantation improves overall survival for UK listed 







This study looks at patients who require a liver transplant to save their lives; this liver 
can be donated by a person who has died either after their heart has stopped 
(donation after cardiac death, DCD) or after the brain has been injured and can no 
longer support life (donation after brainstem death, DBD).  
We know that livers donated after brainstem death function better than those after 
cardiac death, but there are not enough of these livers for everyone, so we wished to 
help patients to decide whether it was better for them to accept an early offer of a 
DCD liver than waiting longer to receive a “better” liver from a DBD donor. 
We found that patients were more likely to survive if they accepted the offer of a liver 




 This study details the UK experience of DCD liver transplantation: 
o Confirming outcomes for DCD are inferior to DBD liver transplantation.  
o Identifying a survival advantage in accepting a DCD offer rather than 
waiting for a “better” DBD liver. 
o This is most pronounced in patients with more advanced disease.  
 Impact on clinical practice 
o Facilitating discussions with individuals about accepting or declining a DCD 
liver offer.  







Rates of liver failure are increasing dramatically in the UK 1 and over a million people 
worldwide die of cirrhosis every year 2. Liver transplantation is the only effective 
treatment for end-stage liver disease and provides an average of 17-22 years of 
additional life 1 3 4. Access to liver transplantation is limited by donor organ availability, 
and over the last decade, as the incidence of liver disease has increased 1, the 
number of patients on the liver transplant waiting list in the UK has roughly doubled. 
Consequently, by two years, about 13% of listed patients will no longer be eligible for 
liver transplantation because of death or deterioration in their condition 5 6. These 
waiting-list pressures have prompted focus on the use of organs from donation after 
circulatory death (DCD) donors, with numbers of DCD donors increasing markedly 
over the last decade, such that they now almost match annual numbers of donation 
after brain death (DBD) donors in the UK 5. Worldwide, only the Netherlands 
achieves similar numbers of DCD donors per million population 7. 
While this increase in DCD donor activity has transformed UK transplant practice, 
DCD organs are generally regarded as sub-optimal, because of the additional warm 
ischaemic ‘hit’ they are subject to during retrieval. Published series report higher 
incidences of primary non-function (PNF) and ischaemic cholangiopathy following 
DCD liver transplantation, resulting in inferior short and long-term outcomes 8-15. 
These poorer outcomes for DCD transplantation have undoubtedly influenced the 
decision to select a particular liver for transplantation, and it is notable that in the UK, 
a much higher proportion of kidneys than livers are transplanted from potential DCD 
donors 5. This is emblematic of a wider challenge posed to the transplant community: 
whether the increasing demand for transplantation merits increased utilisation of less 
optimal organs that are associated with poorer outcomes. Available evidence 
suggests that, despite the potential for such organs to increase liver transplant 
numbers substantially, decline in the quality of available organs often results in 
decreased utilisation rates 16. This may reflect that the responsible clinician often 
finds it difficult to justify, for a particular individual, the use of a ‘marginal’ liver organ 
that is associated with higher morbidity and mortality than would be anticipated with a 
more optimal liver graft. Such a consideration overlooks, however, the potential for 
excess deaths while waiting for that more optimal organ.  
Thus, key to increased utilisation of marginal or DCD liver allografts is whether their 




Addressing the important question of whether a recipient should accept a “poorer 
quality” DCD organ or wait longer for a “better” DBD organ is, however, difficult, and 
a prospective trial would raise challenging practical and ethical concerns. Here, we 
perform a cohort analysis of the NHS Blood and Transplant (NHSBT) UK Transplant 
Registry (UKTR); a prospectively maintained database that records outcomes from 
listing for liver transplantation for all UK patients, and that includes data on over 1400 
DCD liver transplants that have now been performed in the UK. We show that 
outcomes following DCD liver transplants are poorer than following DBD liver 
transplantation, but that the individual’s survival prospects are enhanced by 






MATERIALS & METHODS  
Study design and setting  
Livers from controlled DCD donors (Maastricht category 3), defined as donors 
awaiting circulatory arrest after withdrawal of life-supporting treatment (WLST) 17, 
were included. Since April 2010, organ retrieval was performed by dedicated 
National Organ Retrieval Service (NORS) teams, according to a nationally agreed 
protocol 18. In brief, WLST occurred in the intensive care unit or anaesthetic 
room, and vital signs from the time of withdrawal until cardiac arrest, defined as 
the ‘agonal phase’, were continuously monitored. Pre-mortem interventions, 
(such as heparin administration) aimed specifically at facilitating organ donation, 
are not permissible in the UK. After cardiorespiratory arrest, a ‘stand-off’ time of 
five minutes was observed before death was confirmed by an independent 
medical practitioner and procurement could begin 19. Although UK organ retrieval 
teams wait a minimum of three hours from WLST before abandoning retrieval 20, 
liver donation is typically only pursued for the first hour.  
DCD retrieval proceeded using a rapid retrieval technique, via a midline 
laparotomy, with dual aortic and portal venous perfusion with University of 
Wisconsin solution (ViaSpanTM, Bristol-Myers Squibb Pharma, Garden City, NY, 
USA) containing 25,000 units of heparin per litre in the first two bags. Topical 
cooling was achieved with crushed frozen saline. UK NORS teams routinely wait 
three hours from WLST before abandoning retrieval if cardiorespiratory arrest has 
not occurred 20, but the duration of agonal phase for DCD livers implanted was 
considerably shorter (median (IQR) 15 minutes (11, 20)). During the study period, 
50 DCD livers were machine perfused, either by Normothermic Regional 
Perfusion (NRP) (n=20) or ex situ immediately following retrieval (n=30); no liver 
was subject to hypothermic machine perfusion. Information recorded at retrieval 
included the retrieval surgeon’s assessment of the liver appearance: either 
‘healthy’ or ‘suboptimal’.   
DCD livers were allocated in the UK according to broadly similar principles to DBD 
livers 21, but with some slight modifications, in that the DCD liver was first offered to 
the designated local centre, and then to two or three regionally linked centres, before 
offering to all remaining centres via a ‘fast-track’ scheme. Selection of a specific 




decision included blood group compatibility, donor and recipient size match, primary 
liver aetiology, and perceived clinical urgency.  
Influence of DCD liver transplantation on post-transplant survival 
Data on 3949 first adult elective NHS group 1 (NHS-entitled) liver-only transplants 
performed in the UK using livers from deceased donors between January 1, 2008 
and December 31, 2015 were analysed. The reported size of the study cohort 
excludes 415 transplants with missing values in one or more of the recipient, 
transplant or donor factors or with missing survival information.   
The primary outcome was 5-year transplant survival after transplantation, which was 
defined as the time from transplant to the earlier of patient death or re-transplant. If a 
patient was alive at the end of the follow-up period or lost to follow-up, then their 
survival was censored at the last known survival date while patients who survived for 
longer than 5-years (1825 days) were censored at 5 years. Unadjusted and adjusted 
survival were estimated and stratified by donor type. Primary non-function (PNF) was 
defined as poor graft function necessitating re-transplantation or culminating in death 
within 14 days, excluding rejection and vascular thrombosis. Graft failure was defined 
as death related to graft failure, or re-transplantation. Cold ischaemic time was 
defined as the time between commencement of cold perfusion in the donor and warm 
re-perfusion in the recipient. 
Impact of accepting a DCD liver compared with waiting for a potential DBD liver 
Data on 5825 UK adult elective NHS-entitled patients who were registered on the 
elective waiting list for first liver-only transplantation between January 1, 2008 and 
December 31, 2015 were analysed. Survival status to May 10, 2017 was extracted 
from the UKTR and the Office for National Statistics (ONS). At this date, 81 patients 
were still active on the transplant list; their outcome was unknown at time of analysis.  
To determine how the extant policy allowing DCD liver utilisation affected survival 
from waiting list entry compared to excluding DCD-donors and hypothetically waiting 
for DBD livers, the analytical technique of sequential stratification was used 22. This 
technique uses observational data to emulate data from a hypothetical randomised 
trial allowing outcome comparisons between patients who receive a particular 
treatment at a given time and those waiting for a different treatment, akin to the 
analysis performed by Bonser et al 23. The time origin was taken to be the waiting list 




stratum was then formed from each index case and a control group of all patients on 
the transplant list for the same length of time (in days) or longer and eligible to 
receive that same liver (i.e. blood group and size compatible). A control patient who 
received a DBD transplant was followed up until death or last known follow-up post-
transplant and were not censored at time of DBD transplant. However, a control 
patient who received a DCD transplant were censored at the DCD transplant (as they 
would no longer have had the opportunity of a DBD liver) and were then another 
index patient with a separate group of control patients. Although such censoring of 
control patients constitutes informative censoring, an inverse probability of censoring 
weighted (IPCW) approach was not adopted, because this would greatly add to the 
complexity of the analysis. In addition, experience using the UK Transplant Registry 
database suggests that adjustments for non-informative censoring have relatively 
small impact on subsequent inference. 
The survival time of the index case was censored if they were alive at 10 May 2017. 
The survival times of those in the control group were censored either at the time of 
removal (from tumour progression or worsening of clinical condition) from the list (if 
date of death unknown), at the time of transplant from a DCD donor, or at 10 May 
2017 if still alive.  
Statistical Analysis 
Donor, recipient, and transplant characteristics were compared, stratified by donor 
type, using Fisher’s exact test, chi-squared, or the Mann-Whitney test, as 
appropriate. Unadjusted transplant survival estimates, stratified by donor type, were 
calculated for different times post-transplant using Kaplan-Meier estimation methods 
and assessed using the log-rank test as was survival conditional on 90 day and 1-
year survival. Cox proportional hazards regression modelling was used to assess 
whether donor type influenced transplant survival after adjusting for the final set of 
relevant risk factors. A stepwise procedure was utilised for variable selection. 
To account for competing risks, cumulative incidence functions for graft failure 
(defined as above) and deaths with a functioning graft were compared between DBD 
and DCD donors using Gray’s test/Fine Gray model for competing risks.  
A stratified Cox regression model was used to estimate the hazard of mortality from 
accepting a DCD donor liver compared to continued waiting for a potential DBD 




age; BMI; log (creatinine); log (bilirubin); log(INR); serum sodium; blood group; 
gender; ethnic origin; disease group; grouped registration year; transplant centre; 
patient location (in-patient, out of hospital); ventilation status; renal replacement 
therapy; ascites; HCV and previous abdominal surgery. Stratification produced 
separate baseline hazards for each of the strata defined by the index cases.  
Multiple imputation (MI) was used to impute values for factors with missing values 
when appropriate. MI was implemented in SAS 9.3, using chained equations. The 
imputation model considered all variables in the analysis but also the outcome 
variables; survival time and censoring indicator. Twenty-one imputation datasets 
were generated, with 50 burn-in iterations preceding each imputation set 24. Data 
from the 415 patients that were excluded (see above) were not imputed, because this 
information was not missing completely at random, and was instead was due to 
particular centres not submitting the required data.   
Public and Patient Involvement 
The draft manuscript has been reviewed by the NHSBT liver patient group) and upon 
confirmation of acceptance for publication, the findings will be disseminated to the 
major UK liver patient groups. 
Patient Consent 
Consent for use of anonymised data for outcome analysis is obtained from patients 







Comparison of outcomes for DCD and DBD liver transplantation  
Of the 3949 transplants performed during the study period, 903 (23%) utilised livers 
from DCD-donors (Table 1). DCD liver transplant activity increased annually 
throughout the study period (Figure s1), although, as previously reported 8, utilisation 
rates differed between different UK liver transplant centres (Table 2). Compared to 
DBD donors, DCD donors were younger, had a lower BMI and were more likely to 
have died from trauma than from a cerebrovascular accident (Table 1). DCD liver 
recipients were more likely to have lower UKELD 25 and MELD 26 scores and less 
likely to have had previous abdominal surgery or be in-patients at the time of 
transplantation (Table 2); this suggested a tendency to select lower risk individuals 
as DCD liver recipients. DCD liver recipients were more likely to have cancer as their 
primary liver aetiology. 
Transplant survival was found to be poorer following DCD liver transplantation, with 
the difference apparent by 90 days and maintained over five years (Figure 1a; 5 year 
survival 69·1% DCD vs. 78·3% DBD; p <0·0001). Patient survival was also poorer 
(Figure 1b). This difference in long-term outcomes is not simply due to differences in 
early post-transplant graft failure or mortality, because the divergence in transplant 
survival outcomes was sustained at five years, conditional on transplant survival 
beyond either the initial 90 days (Figure 1c) or the first year (Figure 1d) after 
transplantation.  
The Cox regression model analysis considered all pre-transplantation factors shown 
in Table 1 and 2. Five risk factors were identified as statistically significant predictors 
of 5-year survival: donor age, recipient age, primary liver aetiology, inpatient status, 
and organ appearance (Table s1). The adjusted hazard ratio (HR) for 5-year survival 
for DCD relative to DBD transplantation was 1·65 (95% CI 1·41, 1·95; p<0·0001). 
There was no statistically significant interaction between donor type and either 
UKELD (HR: 1·61 (1·36, 1·91 for a particular UKELD value) (p=0·15) or primary liver 
aetiology (p=0·75). Thus, although outcomes for DCD liver transplantation are 
generally poorer than for DBD liver transplantation, there does not appear to be a 
specific recipient group for whom DCD liver transplantation is more disadvantageous. 
Competing risk analysis (Figure 2a) demonstrated that the poorer survival for the 




transplantation. This reflects an increased incidence of PNF (3·54% (DCD) vs. 1·25% 
(DBD) p<0·0001). However, the rate of graft failure was also higher at later time 
points, indicating greater on-going attritional graft loss (Figure 2b). Consequently, a 
greater proportion of the DCD liver recipients died from graft failure: in contrast, the 
proportions of patients dying with a working graft were similar (Figure 2c). 
Is it better to accept a DCD liver or wait for a potential DBD liver? 
The above results raise the question of whether it would be better for an individual to 
accept a DCD liver or to defer for a better ‘quality’ DBD liver. Figure 3 depicts 
outcomes for the registrants on the liver transplant list during the trial period. Twenty-
three per-cent (1031/4392) of the patients transplanted received livers from DCD 
donors, generating 1031 strata for the sequentially stratified model. Crucially, this 
model revealed that recipients of DCD donor livers had a substantially lower 
unadjusted hazard of death post-registration relative to remaining on the list for a 
potential DBD-donor transplant (Table 3).  
A number of recipient factors were identified as statistically significant and these 
were incorporated into the stratified Cox model (data not presented). Donor type was 
subsequently added to the model. This approach confirmed that compared to waiting 
for a potential DBD liver, the risk-adjusted HR for post-registration mortality is 
consistent with the unadjusted analysis (Table 3). The survival advantage that the 
sequential stratification models for accepting a DCD liver is illustrated in Figure 4.  
The potential survival benefit of using a DCD liver is influenced by a number of 
principal factors: the rate of de-listing or death while on the waiting list, and the 
survival differences following transplantation for DCD and DBD organs. It was 
notable that over the study period there was a marked difference in waiting list 
outcomes (Figures 5a and 5b), with waiting-list mortality (censored for 
transplantation) significantly greater in the earlier (2008-2011) than in the later (2012-
2015) era. This difference does not appear to reflect differences in access to 
transplantation, because the median time to transplant was similar in both eras (140 
(95% CI 131, 149) and 134 (125, 143) days for 2008-2011 and 2012-2015, 
respectively), and may instead be due to either slight differences in the 
characteristics of the patients listed in the two eras (such as UKELD and the 
requirement for renal support (Table 2)), or to improved management of patients 




was similar (Figure 5c). Notably, despite the improved waiting-list survival in the later 
study era, the analysis revealed that the survival benefit associated with DCD liver 
transplantation was, if anything, greater for the 2012-2015 era (Table 3).   
When is the use of a DCD liver most advantageous? 
The decision to transplant a liver is made following consideration of the perceived 
risk-benefit for a particular patient. The results above raise the question whether 
there are particular recipient circumstances in which the use of a DCD liver would be 
particularly advantageous. In this respect, the use of ‘sub-optimal’ liver organs in 
recipients with particularly advanced liver disease remains controversial. The 
analysis was therefore adapted to assess the relative benefit of using DCD livers in 
recipients with different severity of liver disease, by incorporating the patients UKELD 
score at registration (either as a continuous or categorical variable). UKELD score 
was designed to predict mortality on the UK liver transplant waiting list 25, and similar 
to the US MELD system 26, a higher score indicates more severe liver disease.  As 
shown in Table 4, the survival benefit associated with accepting DCD livers increases 
with the recipient’s UKELD score, such that for every unit increase of UKELD, the 
hazard of death after accepting a DCD liver relative to waiting for a potential DBD 
liver decreases by 0·92 (CI: 0·89, 0·96). This is most strikingly evident when 
considering UKELD as a categorical variable, with the hazard ratio for death 
associated with DCD liver use in patients with particularly severe liver disease 
(UKELD > 62) approximately 1/3 of that calculated for patients with mild disease 
(UKELD – 51-53, Table 4). This analysis therefore provides strong support for a 
policy whereby DCD organs are transplanted preferentially into the sickest patients 
on the waiting list. Similar results were observed when the modelling was performed 







In support of the existing literature 8-14, registry analysis of the UK liver transplant 
outcomes confirms that survival following DCD liver transplantation is poorer than 
following DBD liver transplantation. However, the important findings from this study 
are that accepting a DCD liver conferred a survival advantage over waiting for a more 
optimal DBD liver, and that the survival advantage was greatest for patients with 
more advanced liver disease. Thus, our data suggest that the current policy of 
selecting sicker recipients for “optimal” (DBD) grafts, because of the perception that 
the use of “sub-optimal” (DCD) organs in sicker recipients is associated with 
particularly poor outcomes, may deny these patients an important chance for 
survival.  
Our findings therefore mirror a recent analysis by Mclean et al., that reported that UK 
liver recipients with a MELD score >15 have a significant increase in their quality of 
life from accepting, rather than rejecting, a DCD liver offer 27. However, the Mclean 
analysis was performed by using Markov modelling, and the critical difference is that 
the sequential stratification method adopted in the present study matches a patient 
who receives a DCD liver with all those who were eligible to receive that liver and 
who had been registered for the same number of days. This means that the 
comparison between receiving a DCD liver and waiting for another offer is adjusted 
for time on the registration list; the sequential stratification approach thus essentially 
performs a hypothetical randomised trial.  
Current UK utilisation patterns of deceased-donor organs suggest that concerns 
relating to outcomes continue to limit utilisation of liver grafts from potential DCD-
donors. The outcomes for those DCD livers that were unused during the study 
period, had they been transplanted, is clearly speculative. However, it seems 
probable, given the marked survival advantage for accepting a DCD liver relative to 
waiting for a potential DBD liver, that their use would have further improved survival 
for the listed population, particularly for recipients with more advanced liver disease. 
We anticipate that our analysis will provide the contextual basis for discussing with 
individual patients their relative risks of accepting a DCD liver, and that an 
appreciation of their likely survival benefits from doing so, will change current 




potentially large DCD donor pool, this has the scope to increase liver transplant 
numbers substantially. 
We believe our analysis has important implications for ongoing developments in UK 
liver transplant practice. Most pertinently, the recently introduced UK liver allocation 
scheme 28 allocates livers nationally, to the named recipient with the greatest 
calculated ‘transplant benefit score’. This score ranks recipients according to the 
number of additional years of life they gain from a transplant, and will therefore 
generally prioritise the sickest patients on the waiting list. Only DBD livers are 
currently allocated through the new allocation scheme, and therefore the very group 
of patients who, by a similar transplant benefit evaluation, would likely derive most 
benefit from the potential DCD liver pool, may be denied that opportunity because of 
the presumption they will soon be allocated a DBD liver. Our analysis therefore 
highlights the importance of extending the scheme to additionally incorporate national 
DCD liver offering.  
The second aspect of change in UK liver practice concerns the increasing use of in 
situ or ex vivo warm perfusion of liver organs for transplantation. Although still under 
trial evaluation, these approaches offer the potential for improving outcomes by 
‘resuscitating’ DCD liver organs and for providing an additional means of selecting 
only those livers likely to be associated with favourable transplant outcomes 29-36. Our 
analysis suggests that the real benefit of these approaches would be in increasing 
DCD liver utilisation rates; and further cautions that if warm perfusion technologies 
were associated with a paradoxical decrease in DCD liver transplant rates, then this 
would likely reduce survival of the wait-listed UK liver transplant population. 
Reassuringly, the recent Nasrala study of ex vivo normothermic perfusion reports a 
reduction in DCD liver discard rates 37.  
There are several limitations to our study. We did not consider the potential for living 
donor livers or the presumed quality of the DBD liver in our analysis, and it is 
possible, for example, that survival from listing may be better improved by increased 
use of more ‘marginal’ DBD organs, rather than DCD organs. Against this, only 214 
adult living donor liver transplants were performed in the seven years of the study, 
which is unlikely to have impacted on overall UK survival rates for wait-listed patients. 
Similarly, the definition of an expanded criteria donor for liver transplantation remains 
vague, and often adopts donor criteria that were established as predictors for kidney 




distinct entity from DBD liver transplantation, and hence, the analysis of survival 
benefit for accepting a DCD liver focuses on a real clinical dilemma. The main 
limitation of our study is that, as a registry analysis, it may miss confounding factors 
that are not recorded by the registry. Hence, the use of DCD organs in high-risk 
recipients may have occurred in highly select occasions, with the recipient generally 
considered healthier than evident from the UKELD score. Such individual variation 
would not be captured by the analysis. We think this unlikely, because relatively large 
numbers of DCD transplants (n=192) were performed into the sicker (UKELD ≥ 58) 
recipients.  Similarly, the perceived survival benefit associated with DCD liver 
transplantation pertains to the particular pressures of UK liver transplant practice 
during the study period. This advantage is dependent upon three main factors: the 
mortality on the waiting list, and the survival outcomes following DCD and DBD 
transplantation. Hence alterations in any of these factors would alter the relative 
survival advantage of using a DCD liver, potentially limiting the applicability of our 
findings to other countries; the survival advantage would, for example, be more 
modest or non-existent if waiting list mortality was minimal in a particular country due 
to high DBD donation rates. Notwithstanding, UK liver waiting list mortality is roughly 
equivalent to other EU countries, and if anything less than in the US 39. Reported 
outcomes for DCD liver transplantation in other countries are also broadly similar to 
the UK experience. Hence, it is likely that the DCD-donor pool will offer similar 
survival advantages to the waiting list population in these countries.  
Conclusions  
These limitations notwithstanding, our findings suggest that there needs to be a 
better evaluation of the risks associated with waiting for liver transplantation, and that 
an increased awareness of the survival benefit associated with DCD liver 
transplantation, particularly for those recipients with the more severe disease, would 
likely lead to wholesale changes in liver transplant practice. Such a change in 
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 Table 1: Donor and transplant characteristics for first UK adult elective deceased donor 
liver only transplants, 1 January 2008 to 31 December 2015, by donor type. 
 
Data are median (IQT) or number (%) as appropriate. Characteristics were compared, stratified by 
donor type, using chi-squared, fishers exact or Kruskal-Wallis test as appropriate. 
 
Variable Level DBD (N=3046) DCD (N=903) p-value 
 
     
Donor     
     
Donor age (years) Linear 50 (39 - 61) 49 (35 - 59) <0·0001 
     
Donor BMI 
(kg/m2) 
Linear 25·91 (23·31 – 29·05) 25·08 (22·63 – 27·69) <0·0001 
     
Donor blood 
group 
O 1206 (39%) 422 (47%) <0·0001 
 A 1361 (45%) 380 (42%)  
 B 337 (11%) 91 (10%)  
 AB 142 (5%) 10 (1%)  
 
    
Donor gender Male 1538 (50%) 542 (60%) <0·0001 
 Female 1508 (50%) 361 (40%)  
 
    
Donor grouped 
cause of death 
CVA 2092 (69%) 465 (52%) <0·0001 
RTA 124 (4%) 75 (8%)  
 Other trauma 129 (4%) 43 (5%)  
 Miscellanous 701 (23%) 320 (35%)  
     
History of 
diabetes 
No history of 
diabetes 
2765 (91%) 845 (94%) 0·03 
 History of 
diabetes 




82 (3%) 17 (2%)  
     
Transplant 
related 
    
     
Blood group 
match 
Identical 3009 (99%) 879 (97%) 0·002 
Compatible 37 (1%) 24 (3%)  
 
Liver transplanted Whole 2714 (89%) 902 (100%) <0·0001 
Reduced 5 (0%) 1 (0%)  




Healthy 2117 (69%) 504 (56%) <0·0001 
Suboptimal 598 (20%) 270 (30%)  




  Linear 529 (430 - 636) 429 (365 - 488) <0·0001 






Table 2 Recipient characteristics for first UK adult elective deceased donor liver only 
transplants, 1 January 2008 to 31 December 2015, by donor type  
 
Data are median (IQT) or number (%) as appropriate. Characteristics were compared, stratified by 
donor type, using chi-squared, fishers exact or Kruskal-Wallis test as appropriate 
 
 
Variable Level DBD (N=3046) DCD (N=903) p-value 
     
Age (years)  55 (46 - 61) 56 (49 - 62) 0·00040 
     
Blood group O 1202 (39%) 411 (45%) 0·00018 
A 1332 (44%) 371 (41%)  
 B 341 (11%) 97 (11%)  
 AB 171 (6%) 24 (3%)  
     
Gender Male 2019 (66%) 619 (69%) 0·20 
     
Ethnic group White 2675 (88%) 782 (87%) 0·26 
 Asian 244 (8%) 74 (8%)  
 Black 70 (2%) 24 (3%)  
 Chinese/South East Asian 23 (1%) 14 (1%)  
 Other 34 (1%) 9 (1%)  
     
Disease 
aetiology 
Cancer 673 (22%) 289 (32%) <0·0001 
 Hepatitis C cirrhosis 
(HCV) 
334 (11%) 99 (11%)  
 Alcoholic liver disease 
(ALD) 
731 (24%) 217 (24%)  
 Hepatitis B cirrhosis 
(HBV)  
32 (1%) 11 (1%)  
 Primary sclerosing 
cholangitis (PSC) 
348 (11%) 64 (7%)  
 Primary biliary cirrhosis 
(PBC) 
267 (9%) 100 (11%)  
 Auto-immune & 
Cryptogenic disease (AID) 
219 (7%) 36 (4%)  
 Metabolic liver disease 261 (9%) 58 (7%)  
 Other liver disease 181 (6%) 29 (3%)  
     
BMI (kg/m2)  26·73 (23·49 - 30·68) 26·5 (23·88 - 29·67) 0·28 
     
Creatinine 
(µmol/l) 
 78 (64 - 98) 79 (64 - 98) 0·80 
     
Bilirubin 
(µmol/l) 
 49 (25 - 103) 39 (21 - 75) <0·0001 
     
INR  1·4 (1·2 - 1·7) 1·4 (1·2 - 1·7) 0·00063 
     
Sodium 
(mmol/l) 
 137 (134 - 140) 138 (135 - 140) <0·0001 
     
Albumin (g/l)  31 (26 - 36) 32 (28 - 38) 0·0022 
     
Potassium 
(mmol/l) 
 4·2 (3·9 - 4·5) 4·2 (3·9 - 4·5) 0·14 
     
UKELD  55 (51 - 59) 53 (50 - 57) <0·0001 
     
MELD  16 (12 - 21) 15 (11 - 19) <0·0001 
     
Waiting time 
(days) 




     
In-patient 
status 
Inpatient 469 (15%) 91 (10%) <0·0001 
     
Ventilation 
status  
Ventilated 26 (1%) 5 (1%) 0·37 




Renal support 149 (5%) 46 (5%) 0·81 
     
HCV status HCV positive 647 (21%) 233 (26%) 0·0038 




Prior abdominal surgery 401 (13%) 63 (7%) <0·0001 
     
Encephalopa
thy status 
Encephalopathy 940 (31%) 261 (29%) 0·26 





  Ascites 1669 (59%) 465 (51%) 0·081 




Newcastle 194 (6%) 23 (3%) <0·0001 
Leeds 475 (16%) 111 (12%)  
Cambridge 359 (12%) 124 (14%)  
Royal Free 371 (12%) 84 (9%)  
Kings College 460 (15%) 183 (20%)  
Birmingham 725 (24%) 297 (33%)  







Table 3 Unadjusted and risk-adjusted hazard ratio of death for accepting a DCD liver 
relative to waiting for a potential DBD liver 
 
 Full time period 2008-2011 2012-2015 
 N HR (95% CI) N HR (95% CI) N HR (95% CI) 
       
Unadjusted  5798 0·65 (0·55, 
0·77) 
2640 0·74 (0·60, 
0·91) 
3158 0·58 (0·43, 
0·77) 
       
Risk-
adjusted 
5798 0·55 (0·47, 
0·65) 
2640 0·63 (0·51, 
0·78) 
3158 0·44 (0·32, 
0·59) 







Table 4 Risk-adjusted hazard ratio of death for accepting a DCD liver relative to waiting 
for a potential DBD liver for UKELD 
 
 Full time period 2008-2011 2012-2015 
 N HR (95% CI) N HR (95% CI) N HR (95% CI) 
       
Linear UKELD 
 
5798 0·92 (0·89, 
0·96) 
2640 0·91 (0·87, 
0·95) 
3158 0·92 (0·87, 
0·97) 
       
UKELD 
categories 
      
51-53 1288 0·61 (0·42, 
0·91) 
562 0·54 (0·32, 
0·92) 
726 0·79 (0·44, 
1·43) 
54-57 1607 0·48 (0·34, 
0·67) 
762 0·63 (0·43, 
0·92) 
845 0·23 (0·10, 
0·51) 
≥58 1584 0·40 (0·27, 
0·56) 
756 0·40 (0·25, 
0·64) 
828 0·34 (0·19, 
0·62) 




739 1·16 (0·81, 
1·66) 
318 1·66 (1·03, 
2·68) 





4580 0·55 (0·45, 
0·66) 
2081 0·62 (0·49, 
0·79) 
2499 0·43 (0·30, 
0·63) 
Top tier (≥63) 479 0·19 (0·07, 
0·50) 
241 0·17 (0·04, 
0·70) 
238 0·16 (0·04, 
0·64) 








Figure 1: Survival following DCD and DBD liver transplantation 
Kaplan-Meier analysis of: (A) transplant survival, defined as time to patient death or 
liver re-transplantation, and (B) patient survival, for DCD and DBD liver transplants 
performed during the study period. The difference in five-year transplant survival 
between DCD and DBD liver transplantation was not solely a consequence of early 
graft failure or patient death because differences were maintained conditional upon 
transplant survival to 90 days (C) or one year (D). 
 
Figure 2: Graft and patient outcomes following DCD and DBD liver 
transplantation 
Competing risk analysis was performed to compare outcomes following DBD (left 
panel) and DCD (right panel) liver transplantation with death with functioning graft 
and graft failure as competing risks (A). Graft failure includes those patients who 
either underwent re-transplantation or died secondary to graft failure. Rates of graft 
failure are depicted in greater detail in (B). Rates of death with a functioning graft 
were similar in the DBD and DCD cohorts (C). 
Figure 3: Outcomes from registration for transplantation from 2008 to 2015 
1 
Includes: patients registered on the transplant list prior to 1 January 2008 (n=153); 
patients transplanted but not registered for a transplant with NHSBT (n=27); patients 
previously registered for a liver transplant (n=17); multi-organ registration but 
received a liver only (n=9); patients classed as paediatric at registration but adult at 
time of transplant (n=4); patients only ever suspended on the transplant list and 
never activated (n=6); and missing INR at registration (n=5), 
2 Includes patients with: missing cold ischaemia time (n=332); missing donor height 
or height<127cm (n=8); missing donor weight or weight ≥ 150kg (n=10); INR at 
transplant not reported (n=13); serum albumin at transplant not reported (n=9); 
potassium at transplant not reported (n=10); bilirubin at transplant not reported (n=4); 
serum sodium at transplant not reported (n=2);  serum creatinine at transplant not 






Figure 4: Graphical depiction of sequential stratification modelling  
Actual survival from waiting-list registration for liver transplantation during trial period 
(current practice), and estimated survival if DCD livers were excluded from the donor 
pool, and patients instead had to wait for DBD liver offers. Time 0 relates to the time 
of registration / listing for liver transplantation. The curves were calculated by taking 
median survival time post-transplant from the estimated risk-adjusted survival curve 
and plotting an illustration of the survival time post-transplant, assuming an 
exponential distribution.  
 
Figure 5: Registration and transplant outcomes according to listing year. 
Kaplan-Meier patient survival (censored for transplantation) from point of listing for 
transplantation; according to year of listing (A). Broadly, survival from listing differs 
for two eras (2008 to 2011 and 2012 to 2015 (B)). In contrast, survival from 
transplantation (C) was similar in the two eras and consistently poorer for DCD liver 
transplantation.  
  
Figure 1  
Number at risk 
DBD    3046      2479      1944        1495        1130      800  
DCD      903        658        474           347         247      160 
 
                3046       2562      2016        1562      1195        847  
                 903          718        520          376        267        172 
A 
                        90 day                1 year                    5 year  
DBD    93·9 (93·0, 94·7)   90·3 (89·2, 91·3)   78·3 (76·4, 80·0)  
DCD    88·9 (86·7, 90·8)   83·7 (81·1, 85·9)   69·1 (65·1, 72·7)  
Log-rank         <0·0001              <0·0001               <0·0001   
     90 day                     1 year                    5 year  
96·5 (95·7, 97·1)   93·2 (92·3, 94·1)  82·6 (80·8, 84·2)  
94·8 (93·1, 96·1)   91·5 (89·4, 93·1)  78·1 (74·1, 81·5)  
      0·023                      0·062                    0·0087 
 
C D 
Number at risk 
 DBD                     2479       1944       1495      1130        800  
 DCD                       658         474         347        247        160 
  
         1944       1495        1130        800  
           474         347          247        160 
                       1 year                 3 year                5 year  
DBD    96·1 (95·4, 96·8)    89·8 (88·5, 91·0)    83·4 (81·5, 85·1) 
DCD    94·1 (92·2, 95·5)    85·3 (82·2, 87·8)    77·7 (73·5, 81·3) 
Log-rank          0·011                0·0003                0·0003 
p-value 
        3 year                    5 year  
 93·4 (92·3, 94·4)       86·7 (84·9, 88·3) 
 90·6 (87·8, 92·9)        82·6 (78·3, 86·1)  
        0·0095                  0·0094 
B 
  









































                             90 day                1 year           5 year 
DBD                4·8 (4·0, 5·6)        7·4 (6·5, 8·3)      14·4 (13.0, 16.0) 
DCD                9·4 (7·6, 11.4)   13·8 (11·6, 16·2)    23·3 (20·1, 26·7) 
Greys test for      <0·0001              <0·0001                   <0·0001  
equality  
   90 day                   1 year           5 year 
1·4 (1·0, 1·9)      2·5 (2·0, 3·2)    8·5 (7·2, 9·9) 
1·9 (1·1, 3·0)      2·9 (1·9, 4·2)    9·9 (7·1, 13·3) 











Although outcomes from DCD is inferior to DBD liver transplantation (A), the 
survival benefit of accepting an early offer of a DCD liver transplant is significant 





Survival advantage for patients accepting a 
circulatory death liver transplant offer 
 
HIGHLIGHTS 
 This study details the UK experience of DCD liver transplantation: 
o Confirming outcomes for DCD are inferior to DBD liver transplantation.  
o Identifying a survival advantage in accepting a DCD offer rather than 
waiting for a “better” DBD liver. 
o This is most pronounced in patients with more advanced disease.  
 Impact on clinical practice 
o Facilitating discussions with individuals about accepting or declining a DCD 
liver offer.  
o Providing strong support for the use of DCD livers in all patients. 
 
 
